Guerbet
France - VillepinteBiotechnology
Focus: Guerbet is a French public biotechnology company specializing in contrast agents and injectors for diagnostic imaging across oncology, nephrology, cardiovascular, gastroenterology, and neurology. The company is a focused player in the niche but strategically important contrast media market.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Guerbet
AI assessmentNot HiringNo open roles listed right now. Follow Guerbet to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
9 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Declining
LOE Approaching
Flagship contrast agent facing loss of exclusivity; core revenue generator under erosion pressure.
Help build intelligence for Guerbet
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.